CSRD Ireland: Where Pharma Stands Now
CSRD compliance in Ireland's pharmaceutical sector is progressing
Back in February and March, CSRD sustainability reporting rules were narrowed considerably for companies across the EU, Irish pharma included. Several months on, it is a good moment to take stock of what actually changed, who is still in scope, and what is coming next, with a new milestone due in September that is worth having on your radar.
This article covers:
- What CSRD is and why it applied so broadly in the first place
- What the Omnibus 1 Directive changed, and where things stand today
- Who is still in scope, and who has more breathing room
- What to watch for as the September ESRS milestone approaches
- Why energy visibility is worth keeping even if you are no longer required to report
What Is CSRD and Why Did It Apply So Broadly
The Corporate Sustainability Reporting Directive was designed to give companies, investors and regulators a consistent, comparable way to understand a business's environmental and social impact. It was transposed into Irish law through the European Union Corporate Sustainability Reporting Regulations, and it expanded reporting obligations well beyond the large listed companies who had faced similar rules before. For a period, many mid-sized pharmaceutical and life sciences companies in Ireland were bracing to fall under its scope, along with the detailed disclosure and assurance requirements that come with it.
What the Omnibus 1 Directive Changed, and Where Things Stand Today
The Omnibus 1 Directive was published in late February and took effect on 18 March 2026. It amends both CSRD and the Corporate Sustainability Due Diligence Directive, and the headline change is a significant reduction in scope. Only the largest companies and groups now fall under mandatory CSRD reporting. Industry estimates suggest that only around 250 entities in Ireland are likely to remain in scope under the revised rules, a sharp drop from the numbers originally expected to report. For due diligence obligations under CS3D, the timeline has also moved out, with member states given until 2028 to transpose the changes and in-scope companies not required to comply until 2029.
Five months on, Ireland is now in the transposition window, with a deadline of March 2027 to bring the CSRD amendments into national law. Nothing further has been formally confirmed on the Irish side yet, so for now the EU-level rules give the clearest picture of where things are heading.
For a sector like pharma, where mid-sized manufacturing sites and subsidiaries of larger multinationals are common, this has been a meaningful shift. Companies that were resourcing up for full CSRD compliance may find themselves outside the mandatory scope entirely, at least for now.
The Omnibus 1 Directive was published in late February and took effect on 18 March 2026
Who Is Still in Scope
The largest companies and groups, including those already reporting under the original CSRD timeline for Wave 1, remain fully in scope. If your company has an average headcount above the relevant threshold, or is a subsidiary of a non-EU parent that meets the specified turnover levels, it is worth checking your position directly rather than assuming the changes apply to you. The detail of Irish transposition has thrown up some deviations from the EU-wide scope in the past, so a quick check with your finance or compliance team is time well spent.
What to Watch for as the September Milestone Approaches
The next date worth having on your radar is 18 September 2026. The European Commission is due to adopt a revised, simplified set of European Sustainability Reporting Standards by then, which will shape exactly what in-scope companies need to disclose and how. If your company is still within CSRD scope, this is the point where the practical detail of your reporting obligations should become much clearer. If you fall outside scope for now, it is still worth keeping an eye on this milestone, since it will give a good indication of how the broader reporting landscape is settling.
What to Do if Your Obligations Have Been Pushed Out
If you now find yourself outside mandatory scope, the temptation is to shelve any sustainability data work that was underway. That is understandable, but worth resisting for a couple of reasons. First, the direction of travel across EU policy has consistently been towards more transparency over time, not less, so scope is likely to widen again eventually. Second, many of the customers, investors and partners that Irish pharma companies work with will keep asking for this information regardless of what the law strictly requires, particularly if they themselves remain in scope and need it from their own supply chain.
Why Energy Visibility Still Makes Sense Either Way
This is really the heart of it. Whether or not your company is required to report under CSRD this year, understanding your energy use, where it goes, and how efficiently your key systems are running is useful information on its own terms. It helps with cost control, with planning capital investment, and with responding quickly whenever the next regulatory shift comes along. Regulation will keep moving, sometimes tightening and sometimes easing, as we have seen this year with the Omnibus changes. Good energy data is one of the few things that holds its value no matter which way it moves.
At Watt Footprint, we help pharmaceutical and manufacturing sites across Ireland build that visibility, so that compliance, whenever it applies, is a formality rather than a scramble.
